Vaxart Inc. has announced the receipt of substantial funding for its ongoing COVID-19 vaccine development efforts. The funding, valued at up to $460.7 million, comes under Project NextGen, an initiative by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services $(HHS)$. This initiative, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), aims to accelerate the development of next-generation COVID-19 vaccines and therapeutics. Vaxart's project is supported through the Rapid Response Partnership Vehicle (RRPV) Consortium, highlighting a collaborative effort with multiple organizations to advance innovative vaccine solutions.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。